LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Gossamer Bio Inc

Fermé

SecteurSoins de santé

1.1 -3.51

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.1

Max

1.12

Chiffres clés

By Trading Economics

Revenu

-3.6M

-37M

Ventes

510K

9.9M

BPA

-0.16

Marge bénéficiaire

-370.492

Employés

144

EBITDA

-1.9M

-34M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+688.29% upside

Dividendes

By Dow Jones

Prochains Résultats

8 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

23M

273M

Ouverture précédente

4.61

Clôture précédente

1.1

Sentiment de l'Actualité

By Acuity

50%

50%

151 / 381 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Gossamer Bio Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

31 mai 2025, 10:30 UTC

Actualités

Pension Funds Won't Save the Bond Market -- Heard on the Street -- WSJ

31 mai 2025, 06:30 UTC

Résultats

5 Things We've Learned From Retail Earnings -- Barrons.com

31 mai 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 mai 2025, 23:51 UTC

Acquisitions, Fusions, Rachats

Trump Raises Steel Tariffs, Saying U.S. Steel Will Remain U.S.-Controlled -- Update

30 mai 2025, 21:30 UTC

Actualités

Stocks Shrug Off Trade War to Post Best Month Since 2023 -- WSJ

30 mai 2025, 21:15 UTC

Actualités

The Score: E.l.f. Beauty, Tesla, Nvidia, and More Stocks That Defined the Week -- WSJ

30 mai 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

30 mai 2025, 20:44 UTC

Acquisitions, Fusions, Rachats

Bill Ackman Is Killing It. A New ETF Will Track His Investments. -- Barrons.com

30 mai 2025, 20:24 UTC

Actualités

Major U.S. Stock Indexes Finish About Flat; U.S.-China Trade Friction Renews -- WSJ

30 mai 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 mai 2025, 19:44 UTC

Market Talk

Gold Breaks 4-Month Winning Streak -- Market Talk

30 mai 2025, 19:38 UTC

Market Talk

Companies Delay or Cancel $14B In Clean-Energy Investments -- Market Talk

30 mai 2025, 19:29 UTC

Résultats
Acquisitions, Fusions, Rachats

NRG Energy and UnitedHealth Are the S&P 500's Best and Worst for May. Here's Why. -- Barrons.com

30 mai 2025, 19:14 UTC

Market Talk

Oil Settles Lower Ahead of OPEC+ Output Decision -- Market Talk

30 mai 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Fall Awaiting Hotter Weather -- Market Talk

30 mai 2025, 18:51 UTC

Market Talk

Canada's Retaliatory Tariffs Help Fuel Sizable Rise in Tax Revenue -- Market Talk

30 mai 2025, 18:37 UTC

Market Talk
Résultats

Costco Well Positioned for Sustainable Growth, UBS Says -- Market Talk

30 mai 2025, 18:04 UTC

Actualités

S&P 500 Falls After More Trump-China Friction -- WSJ

30 mai 2025, 17:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 mai 2025, 17:47 UTC

Market Talk

Time for BoC Gov. Macklem to Cut Rates, Desjardins Says -- Market Talk

30 mai 2025, 17:40 UTC

Acquisitions, Fusions, Rachats

Trump Is Praising His U.S. Steel Deal. No One Is Sure What It Means -- WSJ

30 mai 2025, 17:38 UTC

Market Talk

U.S: Oil Rig Count Falls for Fifth Straight Week -- Market Talk

30 mai 2025, 17:31 UTC

Market Talk

Costco Well Positioned to Gain Share Amid Tariffs, Baird Says -- Market Talk

30 mai 2025, 17:14 UTC

Actualités

American Consumers Are Still Gloomy on the Economy -- 3rd Update

30 mai 2025, 16:31 UTC

Résultats

Ulta Beauty Stock Is Rising. Earnings Strength Was More Than Cosmetic. -- Barrons.com

30 mai 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

30 mai 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

30 mai 2025, 16:16 UTC

Actualités

S&P 500 Falls After Trump Hits Out at China -- WSJ

30 mai 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 mai 2025, 16:14 UTC

Actualités

HSBC Retreats From Banking Smaller U.S. Businesses -- WSJ

Comparaison

Variation de prix

Gossamer Bio Inc prévision

Objectif de Prix

By TipRanks

688.29% hausse

Prévisions sur 12 Mois

Moyen 8.75 USD  688.29%

Haut 15 USD

Bas 4 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

5

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

1.06 / 1.23Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

151 / 381Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.